Cannabix Technologies (BLO) AI Stock Analysis

• Market Cap: C$85.96M
• Dividend Yield: N/A
• Average Volume (3M): 36.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: -52.41%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 121,074,104
• 10 Day Avg. Volume: 30,616
• 30 Day Avg. Volume: 36,452
• PEG Ratio: -0.30
• Price to Book (P/B): 27.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -37.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: C$0.73 ▲(21.00% Upside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

Score is held down primarily by very weak financial performance (minimal revenue, large losses, and ongoing cash burn). Technicals provide partial support due to a strong uptrend above key moving averages, but overbought momentum signals add near-term risk. Valuation offers limited support because profitability is negative and no dividend yield is provided.

Positive Factors

Low leverage / modest debt

Low absolute debt and a very low debt-to-equity ratio materially reduce near-term solvency risk and interest burden. This balance-sheet conservatism gives the company more strategic flexibility to pursue R&D, partnerships or staged commercialization without immediate refinancing pressure.

Niche breath-testing technology focus

A focused product strategy on breath-based cannabis and alcohol detection addresses regulatory and safety needs across law enforcement, workplace testing and consumer markets. This specialized niche creates a defensible product roadmap and clear addressable markets if technical and regulatory validation are achieved.

Signs of improving free cash flow

Periodic improvements in free cash flow indicate the company may be making operational progress or cost efficiencies. Sustained improvement would reduce funding needs, extend runway for commercialization, and make partnerships or modest capital raises less dilutive over the medium term.

Negative Factors

Minimal revenue, deep losses

The company remains far from commercial scale, generating negligible revenue while incurring significant operating losses. This structural shortfall shows product-market adoption is not yet established, making sustained profitability contingent on successful commercialization or new revenue streams.

Persistent negative cash flow and burn

Ongoing operating and free cash outflows create a durable financing need that can force dilution, distract management, or constrain investment in product development and commercialization. Continued negative cash flow increases execution risk unless offset by partners or new funding sources.

Erosion of equity and negative returns

Material declines in equity and persistently negative ROE signal shareholder value erosion and likely dilution from financing. This weakens financial flexibility, elevates cost of capital over time, and can hamper the company's ability to secure strategic partners or attract long-term investors.

Cannabix Technologies Business Overview & Revenue Model

Company Description

Cannabix Technologies Inc., a technology company, develops marijuana breathalyzer for employers, law enforcement, governments, and public in North America. It develops tetrahydrocannabinol breath analyzers, a point of care breath testing tool for the rapid detection of recent cannabis use, as well as breath collection units. The company was formerly known as West Point Resources Inc. and changed its name to Cannabix Technologies Inc. in August 2014. Cannabix Technologies Inc. was incorporated in 2011 and is based in Burnaby, Canada.

How the Company Makes Money

null

Cannabix Technologies Financial Statement Overview

Summary

Financial profile is very weak: TTM revenue is minimal (~$0.12M) with deeply negative profitability and large operating/net losses, alongside continued cash burn (TTM operating and free cash flow about -$2.0M). The main offset is low leverage (modest debt and low debt-to-equity), but equity has declined and returns are strongly negative, highlighting ongoing funding/execution risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is minimal (~$0.12M) and profitability is deeply negative, with gross profit below zero and large operating and net losses (net margin roughly -51x sales). Annual results also show limited/zero revenue in recent years alongside persistent losses, suggesting the company has not yet reached commercial scale and is still in a heavy investment/burn phase. The main positive is that losses appear tied to operating structure rather than leverage, but the current earnings profile is very weak.

Balance Sheet

Leverage is low, with modest total debt (~$0.09M TTM) and a low debt-to-equity ratio (~0.05x), which reduces near-term balance-sheet risk. However, equity has declined materially versus prior years, and returns on equity are strongly negative, reflecting ongoing losses and dilution/erosion of shareholder value. Overall, the balance sheet looks lightly levered but pressured by continued unprofitability.

Cash Flow

Cash generation remains negative: TTM operating cash flow is about -$2.0M and free cash flow is about -$2.0M, indicating continued cash burn to fund operations. While free cash flow has shown improvement in some periods (including a strong TTM growth figure off a negative base), cash flows are still firmly negative and not yet supported by meaningful operating inflows. Free cash flow tracks net losses closely, implying limited non-cash cushioning and continued funding needs.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	123.04K	0.00	0.00	0.00	0.00	6.57M
Gross Profit	-83.38K	-168.52K	-153.24K	-126.29K	-29.22K	-25.57K
EBITDA	-6.14M	-4.55M	-2.96M	-2.01M	-3.11M	-9.11M
Net Income	-6.33M	-4.69M	-3.13M	-2.14M	-3.37M	-9.24M
Balance Sheet
Total Assets	2.17M	3.00M	4.70M	6.95M	8.76M	10.38M
Cash, Cash Equivalents and Short-Term Investments	1.60M	2.35M	4.26M	6.52M	8.45M	10.10M
Total Debt	88.43K	158.65K	154.58K	132.54K	0.00	0.00
Total Liabilities	304.70K	447.71K	248.02K	237.17K	120.84K	80.78K
Stockholders Equity	1.87M	2.55M	4.45M	6.71M	8.64M	10.30M
Cash Flow
Free Cash Flow	-2.05M	-1.86M	-2.11M	-2.00M	-2.13M	-1.79M
Operating Cash Flow	-2.04M	-1.84M	-2.08M	-1.97M	-2.13M	-1.71M
Investing Cash Flow	0.00	-17.54K	-30.96K	-28.65K	-4.59K	-121.81K
Financing Cash Flow	277.08K	-58.47K	-143.53K	10.88K	492.50K	3.49M

Cannabix Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Positive. The current price of 0.6 is below the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.60, and above the 200-day MA of 0.58, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 58.26 is Neutral, neither overbought nor oversold. The STOCH value of 58.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	55 Neutral	C$221.44M	-36.01	-9.93%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$21.58M	-5.28	106.68%	―	28.59%	23.46%
BLO	49 Neutral	C$85.96M	-17.95	-259.71%	―	―	-52.41%
PINK	42 Neutral	C$60.53M	-1.50	-181.70%	―	209.29%	35.38%

Cannabix Technologies Corporate Events

Cannabix Lands First Commercial Sale of Marijuana Breath Test to Major Construction Firm

Cannabix Technologies has recorded its first commercial sale of the Marijuana Breath Test (MBT) system to a major Pacific Northwest construction contractor through an authorized reseller, marking its initial penetration into the construction sector. The MBT is designed to detect recent cannabis use by identifying delta-9 THC in breath within about four hours of consumption, providing employers with a more relevant and defensible tool for managing on-the-job safety than legacy urine, saliva, or hair tests.

The company, which partners with Omega Laboratories for LC-MS analysis of collected breath samples, sees this deployment as a significant milestone in its commercialization strategy. Cannabix expects rising interest from large employers facing regulatory, insurance, and operational pressures, and is positioning the MBT as a potential new standard for recent-use cannabis detection across multiple safety-critical industries while ramping up production and working closely with resellers.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.86 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix launches commercial marijuana breath test targeting recent cannabis use

Cannabix Technologies has begun a phased commercial rollout of its Marijuana Breath Test system, delivering units to select customers in multiple industries and preparing to scale production. The platform combines a handheld Breath Collection Unit, disposable Breath Cartridges and a laboratory-developed test to detect recent cannabis use within roughly four hours of consumption, aiming to give employers and law enforcement a more relevant measure of impairment.

The launch follows independent peer-reviewed validation in the Journal of Analytical Toxicology and integration of the system into Omega Laboratories’ certified drug-testing workflows. Cannabix has established manufacturing, QA procedures and a recurring revenue model based on disposable cartridges, positioning the company to benefit from growing legalization and demand for scientifically grounded, recent-use cannabis detection in safety-critical markets.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.48 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Technologies Raises C$700,000 in Non-Brokered Private Placement

Cannabix Technologies has closed a non-brokered private placement, raising C$700,000 through the issuance of 1.4 million units priced at C$0.50, each comprising one common share and a warrant exercisable at C$0.65 for 24 months with an acceleration feature tied to share price performance. The proceeds will be directed toward manufacturing inventory and labour, general and administrative costs, investor relations, and working capital, with the financing conducted under the listed issuer financing exemption, involving CEO participation deemed a related-party transaction and modest finder’s fees and warrants, while an existing investor waived its contractual participation right for this offering.

The placement units are freely tradable under Canadian securities rules due to the chosen exemption, potentially enhancing liquidity for new investors and supporting Cannabix’s near-term operational funding needs. Insider participation, though below the threshold requiring minority approval, signals internal confidence in the company’s trajectory, while the investor waiver helped streamline the financing and underscores the company’s ability to access capital without diluting pre-existing participation rights in this round.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Marijuana Breath Test Lands Cover Spot in AlcoPro’s 2026 Catalogue

Cannabix Technologies’ Marijuana Breath Test (MBT) has been selected to appear on the cover of AlcoPro Inc.’s 2026 product catalogue, which is distributed to more than 85,000 businesses in the U.S. and abroad, including law enforcement and corrections clients. The feature underscores Cannabix’s growing partnership with AlcoPro in pre-launch marketing of the MBT in the U.S. and highlights the company’s integration of proprietary breath collection technology with LC-MS analysis through its collaboration with Omega Laboratories, positioning Cannabix to gain greater visibility and credibility in the professional drug-testing market as employers seek more accurate and non-invasive tools to address evolving workplace safety and impairment challenges.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.

Cannabix Wins First International BreathLogix Order, Scraps Planned Financing

Cannabix Technologies has secured its first international distributor order for its BreathLogix autonomous alcohol screening devices and accessories from its exclusive Australian partner, Breathalyser Sales & Service Pty Ltd, covering Australia, New Zealand and the Pacific Islands. The BreathLogix system offers rapid pre-access breath alcohol checks, identity-confirming photos, real-time alerts and cloud-based reporting, and can be integrated with site access controls and fleet management systems, positioning it for deployment across industries such as mining, oil and gas, industrial and logistics. Featuring a patent-pending pre-calibrated sensor cartridge to simplify maintenance, the product launch momentum has prompted Cannabix to cancel a planned non-brokered private placement and reassess its near-term capital needs in early 2026, while the company also initiates a short investor awareness campaign to broaden market visibility.

The most recent analyst rating on (TSE:BLO) stock is a Hold with a C$0.59 price target. To see the full list of analyst forecasts on Cannabix Technologies stock, see the TSE:BLO Stock Forecast page.